Greenleaf Trust Decreases Stake in Stryker Corporation $SYK

Greenleaf Trust trimmed its holdings in Stryker Corporation (NYSE:SYK) by 4.5% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 15,228,545 shares of the medical technology company’s stock after selling 709,525 shares during the quarter. Stryker comprises about 46.2% of Greenleaf Trust’s holdings, making the stock its biggest holding. Greenleaf Trust’s holdings in Stryker were worth $4,794,555,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. VanderPol Investments L.L.C. lifted its position in shares of Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares in the last quarter. KCM Investment Advisors LLC raised its position in shares of Stryker by 1.5% during the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after acquiring an additional 28 shares during the last quarter. Rossby Financial LCC raised its position in shares of Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares during the last quarter. Tcfg Wealth Management LLC lifted its stake in shares of Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after acquiring an additional 29 shares during the period. Finally, ICW Investment Advisors LLC boosted its holdings in Stryker by 0.6% in the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock valued at $1,791,000 after acquiring an additional 30 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 2.9%

NYSE SYK opened at $331.32 on Friday. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock’s 50 day moving average price is $329.10 and its two-hundred day moving average price is $331.47. The stock has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is 36.48%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dylan Bram Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on SYK shares. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. BMO Capital Markets assumed coverage on Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective for the company. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. Barclays cut their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Finally, Truist Financial lifted their price target on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.